IMPACT OF EARLY REMEDESIVIR THERAPY ON COVID19 PROGRESSION IN COMMUNITY SETTING

Abstract

Background: The COVID-19 pandemic, caused by SARS-CoV-2, continues to necessitate 
effective treatment strategies. Remdesivir, an antiviral agent, has shown promise in 
hospitalized patients, but its impact in community settings and when administered early in the 
disease course remains underexplored. Methods: This retrospective cohort study analyzed 120 
patients diagnosed with COVID-19 in community settings, split equally into two groups: one 
receiving early Remdesivir therapy within 48 hours of diagnosis and the other not receiving 
Remdesivir. We assessed the impact of treatment on disease progression, time to clinical 
recovery, hospitalization rates, and safety profiles. Results: Early administration of 
Remdesivir was associated with a significant reduction in disease progression, with an odds 
ratio (OR) of 0.05 (95% CI: 0.02, 0.13) for progression. Patients treated with Remdesivir also 
exhibited faster clinical recovery (OR for fast recovery: 1.97, 95% CI: 0.95, 4.10) and lower 
hospitalization rates (OR for hospitalization: 0.29, 95% CI: 0.09, 0.94) compared to those who 
did not receive the drug.